| Dr Eric Arvind Gomes, MD | |
|
3100 Princeton Pike, Lawrenceville, NJ 08648-2300 | |
| (609) 896-1793 | |
| Not Available |
| Full Name | Dr Eric Arvind Gomes |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 29 Years |
| Location | 3100 Princeton Pike, Lawrenceville, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205831807 | NPI | - | NPPES |
| 8364001 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MA069021 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Medical Center Of Princeton At Plainsboro | Plainsboro, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Clinical Health Care Associates Of New Jersey Pc | 0749180198 | 664 |
| Princeton Healthcare Affiliated Physicians Pc | 2567598022 | 66 |
News Archive
A research team from The University of Nottingham has helped uncover a second rare genetic mutation which strongly increases the risk of Alzheimer's disease in later life.
Interfering with inflammatory signals produced by heart muscle cells might someday provide novel therapeutic strategies for atrial fibrillation, according to an international team of researchers who have published their findings in the journal Circulation.
In other market news, coverage continues of the cost and effectiveness of Sovaldi, a new drug to treat hepatitis C, and the related earnings gained by Gilead Sciences, its manufacturer.
Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera's JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson's Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.
› Verified 1 days ago
| Entity Name | Clinical Health Care Associates Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447260435 PECOS PAC ID: 0749180198 Enrollment ID: O20040421001473 |
News Archive
A research team from The University of Nottingham has helped uncover a second rare genetic mutation which strongly increases the risk of Alzheimer's disease in later life.
Interfering with inflammatory signals produced by heart muscle cells might someday provide novel therapeutic strategies for atrial fibrillation, according to an international team of researchers who have published their findings in the journal Circulation.
In other market news, coverage continues of the cost and effectiveness of Sovaldi, a new drug to treat hepatitis C, and the related earnings gained by Gilead Sciences, its manufacturer.
Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera's JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson's Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.
› Verified 1 days ago
| Entity Name | Princeton Healthcare Affiliated Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518194323 PECOS PAC ID: 2567598022 Enrollment ID: O20100413000141 |
News Archive
A research team from The University of Nottingham has helped uncover a second rare genetic mutation which strongly increases the risk of Alzheimer's disease in later life.
Interfering with inflammatory signals produced by heart muscle cells might someday provide novel therapeutic strategies for atrial fibrillation, according to an international team of researchers who have published their findings in the journal Circulation.
In other market news, coverage continues of the cost and effectiveness of Sovaldi, a new drug to treat hepatitis C, and the related earnings gained by Gilead Sciences, its manufacturer.
Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera's JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson's Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric Arvind Gomes, MD 3100 Princeton Pike, Bldg 3, 3rd Floor, Lawrenceville, NJ 08648-2300 Ph: (609) 896-1793 | Dr Eric Arvind Gomes, MD 3100 Princeton Pike, Lawrenceville, NJ 08648-2300 Ph: (609) 896-1793 |
News Archive
A research team from The University of Nottingham has helped uncover a second rare genetic mutation which strongly increases the risk of Alzheimer's disease in later life.
Interfering with inflammatory signals produced by heart muscle cells might someday provide novel therapeutic strategies for atrial fibrillation, according to an international team of researchers who have published their findings in the journal Circulation.
In other market news, coverage continues of the cost and effectiveness of Sovaldi, a new drug to treat hepatitis C, and the related earnings gained by Gilead Sciences, its manufacturer.
Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera's JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson's Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.
› Verified 1 days ago
Michael Roy Dash, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 Franklin Corner Rd, Suite 216, Lawrenceville, NJ 08648 Phone: 609-895-6800 Fax: 609-895-6988 | |
Dr. Neel Jitendra Gandhi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2997 Princeton Pike, #201, Lawrenceville, NJ 08648 Phone: 609-771-0700 Fax: 609-771-8466 | |
Dr. Humaira Naseem Adenwalla, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3100 Princeton Pike Ste D, Lawrenceville, NJ 08648 Phone: 609-910-5556 | |
Dr. Sarah Anne Werbel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3100 Princeton Pike, Bldg 4, Suite I, Lawrenceville, NJ 08648 Phone: 609-896-0303 Fax: 609-896-0308 | |
Dr. Robert Silverbrook, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3131 Princeton Pike, Suite204, Lawrenceville, NJ 08648 Phone: 609-306-8924 Fax: 215-364-3139 | |
Mrs. Daphne Duvalsaint Dadzie, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 168 Franklin Corner Rd, Building 1, Suite 2a, Lawrenceville, NJ 08648 Phone: 609-896-0075 Fax: 609-896-0079 | |
Dr. Jason Hollander, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 168 Franklin Corner Rd Bldg 1, Lawrenceville, NJ 08648 Phone: 609-924-4433 Fax: 609-924-4423 |